Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership
The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator ...
Sangamo Therapeutics’ stock falls the most in 16 years after Pfizer ends hemophilia pact
Sangamo Therapeutics Inc.’s stock tumbled 56% on Tuesday for its second-biggest one-day percentage decline ever, after Pfizer ...
Business Wire2d
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leadi…
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an ...
MM&M3d
Sangamo spirals after Pfizer halts hemophilia A gene therapy partnership
The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...
Benzinga.com5d
9 Analysts Have This To Say About Sangamo Therapeutics
9 analysts have shared their evaluations of Sangamo Therapeutics SGMO during the recent three months, expressing a mix of ...
Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact
Key Takeaways Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement ...
FierceBiotech3d
Pfizer cuts losses on near-approval hemophilia gene therapy, adding to troubled Sangamo's woes
Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec ...
Lost Money on Sangamo Therapeutics, Inc. (SGMO)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...
Sangamo Therapeutics: Left At The Alter (Rating Downgrade)
Sangamo (SGMO) stock faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price ...
Business Wire2d
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz announces an investigation of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) on behalf of inv ...
ETF Daily News3d
Sangamo Therapeutics (NASDAQ:SGMO) Given “Buy” Rating at HC Wainwright
Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The firm had revenue of $49.41 million during the quarter, compared to the consensus estimate ...